Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination

De novo and relapsed immune‐mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to have occurred following severe acute respiratory syndrome coronavirus 2 (COVID‐19) vaccination. Here, we present a case of a 28‐year‐old woman who received the tozinameran (BNT162b2, Pfizer‐BioNte...

Descripción completa

Detalles Bibliográficos
Autores principales: Deucher, William, Sukumar, Senthil, Cataland, Spero R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822264/
https://www.ncbi.nlm.nih.gov/pubmed/35155977
http://dx.doi.org/10.1002/rth2.12658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822264/
https://www.ncbi.nlm.nih.gov/pubmed/35155977
http://dx.doi.org/10.1002/rth2.12658

Ejemplares similares